Ozempic Gastroparesis Attorney: Understanding the Statute of Limitations in New York
Latest update (2026-01)
FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Information to Targeted Risk Assessment
For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context has empowered individuals to make informed decisions about their well-being, often by translating complex biomedical developments into accessible knowledge. Within this tradition, the emergence of new therapeutic agents—such as glucagon-like peptide-1 receptor agonists—has been presented as a significant advancement in managing chronic metabolic disorders. However, as clinical experience with these medications has expanded, so too has the recognition of potential adverse effects that warrant careful attention. Among these, reports of delayed gastric emptying, or gastroparesis, have surfaced in association with certain drug exposures, prompting a shift in focus from general health education to specific risk assessment. This pivot is particularly relevant for individuals who have used such medications and subsequently developed gastrointestinal symptoms that may be linked to their treatment. The transition from a broad informational framework to a targeted concern about occupational or personal exposure now requires a nuanced understanding of how pharmaceutical use intersects with legal and medical accountability. In this context, the question of timely legal recourse becomes paramount, especially for those seeking to address potential harm through the judicial system.
The Link Between Ozempic and Gastroparesis
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which can lead to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction—has emerged as a significant concern. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The link between Ozempic and gastroparesis is supported by mechanistic pathways: GLP-1 receptor agonists delay gastric motility, and prolonged use may exacerbate or unmask underlying gastroparesis. Reported adverse effects from clinical trials show that gastrointestinal reactions occur more frequently with Ozempic than placebo. In placebo-controlled trials, nausea occurred in 15.8% of patients on 0.5 mg and 20.3% on 1 mg, compared to 6.1% on placebo; vomiting occurred in 5.0% and 9.2% on Ozempic versus 2.3% on placebo; and diarrhea in 8.5% and 8.8% versus 1.9% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Abdominal pain was reported in 7.3% and 5.7% of Ozempic-treated patients versus 4.6% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms align with gastroparesis presentation, though the label does not explicitly list gastroparesis as an adverse reaction.
Postmarketing Evidence and Warning Adequacy
Postmarketing reports have raised concerns about retained gastric contents during anesthesia, suggesting delayed gastric emptying persists even after preoperative fasting. The label notes rare reports of pulmonary aspiration in patients on GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, who had residual gastric contents despite adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This indicates that gastric emptying may be significantly impaired, a hallmark of gastroparesis. The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The current label does not specifically warn about gastroparesis as a potential adverse effect. Instead, it lists nausea, vomiting, diarrhea, abdominal pain, and constipation as common gastrointestinal reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label also includes a warning about hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not address the risk of gastroparesis or chronic delayed gastric emptying. This gap in warnings may affect patients who develop persistent symptoms requiring medical intervention.
Legal Considerations and the New York Statute of Limitations
For affected patients, attorney-related considerations include evaluating whether the manufacturer provided sufficient information about the risk of gastroparesis. In New York, the statute of limitations for product liability claims, including failure to warn, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. The timeline between exposure to Ozempic and documented harm is crucial. Clinical trial data show that gastrointestinal adverse reactions often occur during dose escalation, but chronic use may lead to sustained symptoms. Postmarketing reports of pulmonary aspiration suggest that delayed gastric emptying can persist for an extended period, potentially leading to gastroparesis diagnosis months after starting treatment. Patients who experience persistent nausea, vomiting, or abdominal pain should seek medical evaluation for gastroparesis. If diagnosed, they may have a legal claim if they can demonstrate that the manufacturer failed to adequately warn about this risk. The evidence from clinical trials and postmarketing reports supports a mechanistic link, but the label does not explicitly address gastroparesis. This omission may be central to legal arguments regarding inadequate warnings.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is the statute of limitations for Ozempic gastroparesis claims in New York?
In New York, the statute of limitations for product liability claims, including failure to warn, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. It is important to consult with an attorney promptly to ensure your claim is filed within this timeframe.
Does the Ozempic label warn about gastroparesis?
The current Ozempic label does not specifically warn about gastroparesis as a potential adverse effect. It lists nausea, vomiting, diarrhea, abdominal pain, and constipation as common gastrointestinal reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, postmarketing reports have raised concerns about delayed gastric emptying, which is a hallmark of gastroparesis.
What evidence supports the link between Ozempic and gastroparesis?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.